Buck Kristen K 4
4 · LISATA THERAPEUTICS, INC. · Filed Jan 11, 2024
Insider Transaction Report
Form 4
Buck Kristen K
EVP, R&D and CMO
Transactions
- Award
Common Stock
2024-01-09+27,000→ 59,915 total - Tax Payment
Common Stock
2024-01-09$3.08/sh−3,221$9,921→ 56,694 total - Award
Stock Option (Right to Buy)
2024-01-09+14,000→ 14,000 totalExercise: $3.08From: 2024-01-09Exp: 2034-01-09→ Common Stock (14,000 underlying) - Tax Payment
Common Stock
2024-01-09$3.08/sh−2,147$6,613→ 54,547 total - Tax Payment
Common Stock
2024-01-10$3.00/sh−512$1,536→ 54,035 total
Footnotes (5)
- [F1]Represents 27,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
- [F2]Includes 31,400 unvested restricted stock.
- [F3]Shares withheld as payment of a tax liability on vesting of restricted stock.
- [F4]Includes 30,325 unvested restricted stock.
- [F5]One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date.